MAA
ALT icon

Mraz Amerine & Associates’s Altimmune ALT Stock Holding History

Mraz Amerine & Associates’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-67
Closed -$15K – 160
2017
Q1 		$15K Buy
67
+34
+103% +$18.2K ﹤0.01% 154
2016
Q4 		$33K Buy
+33
New +$29.6K 0.01% 159

Other funds holding ALT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FQ
First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Mraz Amerine & Associates's ALT Position: Q2 2017 in Review

Mraz Amerine & Associates sold out of Altimmune (ALT) in Q2 2017, closing a stake of 67 shares — an estimated $15K sold.

Mraz Amerine & Associates first reported a position in ALT in Q4 2016 and held it in 2 quarters. The position peaked at $33K in Q4 2016. 41 funds tracked by Wall St. Rank hold ALT as of Q2 2017.

  • Mraz Amerine & Associates reported no remaining Altimmune position as of Q2 2017 after selling out during the quarter.
  • Mraz Amerine & Associates sold 67 Altimmune shares in Q2 2017, an estimated $15K.
  • Mraz Amerine & Associates first reported a position in Altimmune in Q4 2016 and held it in 2 quarters.
  • Mraz Amerine & Associates's Altimmune position peaked at $33K in Q4 2016.
  • 41 funds tracked by Wall St. Rank held Altimmune as of Q2 2017.

Based on Mraz Amerine & Associates's 13F filing for Q2 2017, filed 27 Jul 2017.